Nanotechnology, Nanomedicine and Artificial Intelligence: Global Health Care Equivalency

This groundbreaking volume explores the vision of a Global Health Care Equivalency (GHCE) system powered by artificial intelligence and quantum computing technologies, operating on secure quantum-encrypted blockchains to create an equitable and decentralized healthcare framework accessible to all people worldwide.

Readers will gain profound insights into how emerging technologies can transform global healthcare delivery through detailed analyses of quantum encryption, blockchain implementation, and AI-driven diagnostics. The book presents a comprehensive roadmap for achieving healthcare equity, offering practical frameworks for technological integration, ethical considerations for implementation, and strategies for overcoming geopolitical barriers to create a truly universal healthcare system.

This visionary work is essential reading for healthcare policy makers, medical technology researchers, AI and quantum computing specialists, global health advocates, and graduate students in healthcare administration, biomedical engineering, and international development. It will particularly benefit professionals working at the intersection of healthcare and emerging technologies who seek to address global health disparities.

Frank J. Boehm has worked as a nanotechnology consultant, technology scout, product designer, research associate, and academic writer/editor for international corporations and university laboratories. Self-taught in nanotechnology and nanomedicine, Frank has developed numerous concepts for advanced nanomedical diagnostic and therapeutic systems. In 2009, he founded NanoApps Medical, Inc. to develop innovative and cost-effective nanomedical solutions for global benefit, and later co-founded NanoApps Athletics, Inc. in 2019. His published works include his first book on nanomedical device design (2013), multiple book chapters, journal articles, and an in-depth paper on ＂Human Brain/Cloud Interface.＂ Currently, Frank is focused on a three-book series exploring the convergence of nanotechnology, nanomedicine, AI, and quantum computing to achieve global healthcare equivalency.

Raj Bawa is president of Bawa Biotech LLC, a biotech/pharma consultancy and patent law firm founded in 2002. Trained as a microbiologist and biochemist, he serves as a registered patent agent, scientific advisor to Teva Pharmaceutical Industries (since 2010), professor at Northern Virginia Community College (since 2004), and vice president/chief IP officer at Guanine, Inc. (since 2016). Dr. Bawa previously worked at the US Patent & Trademark Office (1990s-2002) as a primary examiner. He has led various research initiatives, including a CDC grant to develop an assay for carbapenemase-resistant bacteria. His education includes degrees in microbiology (BSc), cancer biology (MS), biophysics/biochemistry (PhD), and medicine (MD). Currently, he co-chairs nanotech and precision medicine committees for the American Bar Association and serves as founding director of the American Society for Nanomedicine. His contributions include over 100 publications, 10 edited texts, and editorial board service for numerous journals. His achievements have been recognized with awards including the Innovations Prize (2008), Appreciation Award from the Undersecretary of Commerce (2001), and Lifetime Achievement Award from the American Society for Nanomedicine (2014).